Javascript must be enabled to continue!
e0506 Application of overlapped sirolimus-eluting stents in treatment of long coronary arteries lesion
View through CrossRef
Objective
To evaluate the clinical efficacy of overlapped Excel and Cypher stents in treatment for long coronary arteries lesion.
Method
374 patients with de-novo long coronary arteries lesion who performed 2 Excel or Cypher stents which diameter varied 2.5 mm ∼ 3.5 mm in department of cardiology, general hospital of CAPF were enrolled in from 2006.8 to 2009.3 retrospectively. These patients were divided to two groups by the type of stents implanted: Excel group and Cypher group. The incidence of composite MACE and stent thrombosis during hospitalisation and 12-month clinical follow-up outside hospital after PCI between two groups were compared, follow-up angiograpy were performed in several patients, and in-stent LLL, in-segemt LLL and incidence of restenosis between two groups were compared.
Result
Clinical characteristics and characteristics of target lesion were similar between two groups, PCI procedure were similar except the ratio of pre-dilatation between two groups. Incidence of composite MACE during hospitalisation after PCI of Excel group and Cypher group were 5.7% and 6.1%, incidence of composite MACE 12-month clinical follow-up outside hospital were 6.6% and 8.8% respectively, incidence of acute/subacute stent thrombosis defined by ARC of Excel group and Cypher group were 2.8% and 2.5%, incidence of late stent thrombosis were 2.7% and 2.7% respectively, there were no significant differences between two groups; incidence of in-stent restenosis of Excel group and Cypher group follow-up were 6.0% and 9.6%, incidence of in-segment restenosis were 9.5% and 12% respectively, that revealed non-significant differences between two groups; in-segment LLL of Excel group and Cypher group were 0.11±0.06 mm and 0.12±0.08 mm, there were no significant differences between two groups, but in-stent LLL were 0.09±0.05 mm and 0.10±0.05 mm respectively, that showed significant difference between two groups (p=0.037).
Conclusion
The safety and efficacy of overlapped Excel stents were similar as overlapped Cypher stents in treatment of long coronary arteries lesion, meanwhile, overlapped Excel stents relieve in-stent LLL than overlapped Cypher stents; LLL of overlapped site was more severe than non-overlapped site, whatever Excel or Cypher stents, but there was no significant difference in ratio of restenosis between overlapped site and any other regions.
Title: e0506 Application of overlapped sirolimus-eluting stents in treatment of long coronary arteries lesion
Description:
Objective
To evaluate the clinical efficacy of overlapped Excel and Cypher stents in treatment for long coronary arteries lesion.
Method
374 patients with de-novo long coronary arteries lesion who performed 2 Excel or Cypher stents which diameter varied 2.
5 mm ∼ 3.
5 mm in department of cardiology, general hospital of CAPF were enrolled in from 2006.
8 to 2009.
3 retrospectively.
These patients were divided to two groups by the type of stents implanted: Excel group and Cypher group.
The incidence of composite MACE and stent thrombosis during hospitalisation and 12-month clinical follow-up outside hospital after PCI between two groups were compared, follow-up angiograpy were performed in several patients, and in-stent LLL, in-segemt LLL and incidence of restenosis between two groups were compared.
Result
Clinical characteristics and characteristics of target lesion were similar between two groups, PCI procedure were similar except the ratio of pre-dilatation between two groups.
Incidence of composite MACE during hospitalisation after PCI of Excel group and Cypher group were 5.
7% and 6.
1%, incidence of composite MACE 12-month clinical follow-up outside hospital were 6.
6% and 8.
8% respectively, incidence of acute/subacute stent thrombosis defined by ARC of Excel group and Cypher group were 2.
8% and 2.
5%, incidence of late stent thrombosis were 2.
7% and 2.
7% respectively, there were no significant differences between two groups; incidence of in-stent restenosis of Excel group and Cypher group follow-up were 6.
0% and 9.
6%, incidence of in-segment restenosis were 9.
5% and 12% respectively, that revealed non-significant differences between two groups; in-segment LLL of Excel group and Cypher group were 0.
11±0.
06 mm and 0.
12±0.
08 mm, there were no significant differences between two groups, but in-stent LLL were 0.
09±0.
05 mm and 0.
10±0.
05 mm respectively, that showed significant difference between two groups (p=0.
037).
Conclusion
The safety and efficacy of overlapped Excel stents were similar as overlapped Cypher stents in treatment of long coronary arteries lesion, meanwhile, overlapped Excel stents relieve in-stent LLL than overlapped Cypher stents; LLL of overlapped site was more severe than non-overlapped site, whatever Excel or Cypher stents, but there was no significant difference in ratio of restenosis between overlapped site and any other regions.
Related Results
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
BACKGROUND:
Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbrevi...
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Two hundred forty-six patients with 252 bifurcation lesions were enrolled into a prospective, nonrandomized study to use paclitaxel-eluting or sirolimus-eluting stent for crush ste...
Sirolimus PK trial: A pharmacokinetic study of the sirolimus‐eluting Bx Velocity stent in patients with de novo coronary lesions
Sirolimus PK trial: A pharmacokinetic study of the sirolimus‐eluting Bx Velocity stent in patients with de novo coronary lesions
AbstractThis study was conducted to assess the systemic drug release and distribution of sirolimus‐eluting stents. Early results with sirolimus‐eluting stents have demonstrated a f...
CLINICAL APPLICATION OF DOMESTIC LONG BIODEGRADABLE POLYMER COATED SIROLIMUS ELUTING STENTS FOR TREATMENT OF LONG CORONARY ARTERY LESIONS
CLINICAL APPLICATION OF DOMESTIC LONG BIODEGRADABLE POLYMER COATED SIROLIMUS ELUTING STENTS FOR TREATMENT OF LONG CORONARY ARTERY LESIONS
Objectives
To evaluate the efficacy and safety of domestic long biodegradable polymer coated sirolimus eluting stents (Excel stent, Shandong JW) for treatment of ...
e0501 1-year clinical outcomes after implantation of sirolimus-eluting stents in patients with coronary artery disease and type 2 diabetes
e0501 1-year clinical outcomes after implantation of sirolimus-eluting stents in patients with coronary artery disease and type 2 diabetes
Background
Drug-eluting stents (DES) have been shown to significantly reduce clinical events and angiographic restenosis in the treatment of coronary artery disea...
The use of drug eluting stents in single and multivessel disease: results from a single centre experience
The use of drug eluting stents in single and multivessel disease: results from a single centre experience
Objective: Drug eluting stents have been shown to reduce the rate of in-stent restenosis in cases where single lesions are treated. The performance of these stents, in patients wit...
Sirolimus-Induced Pneumonitis Following Liver Transplantation
Sirolimus-Induced Pneumonitis Following Liver Transplantation
Abstract
Sirolimus-induced pneumonitis has emerged as a potentially serious complication in renal transplantation but only single case re...
In-stent restenosis in the drug-eluting stent era
In-stent restenosis in the drug-eluting stent era
For the last two decades, restenosis has been considered the most significant problem in interventional cardiology. Drug-eluting stents (DES) have reduced rates of restenosis and t...

